Aurobindo Pharma Limited
AUROPHARMA · NSEValuation
Blended fair value using DCF and peer comparison methods.
Peer comparison
How this company stacks up against sector peers on valuation and quality metrics.
Branded generics & specialty pharma · 8 peers · sector medians shown
| Company | Mkt Cap | P/E | P/B | EV/EBITDA | ROE | Net Margin | Rev CAGR 3y |
|---|---|---|---|---|---|---|---|
Aurobindo Pharma Limited AUROPHARMA · you | ₹86,821 Cr | 24.9× | 2.3× | 12.9× | 9.2% | 10.4% | 10.6% |
| Sector median | — | 32.4× | 4.4× | 27.4× | 14.2% | 14.6% | 12.1% |
| Torrent Pharmaceuticals TORNTPHARM | ₹1.5 L Cr | 70.0× | 18.1× | 36.5× | 25.8% | 15.5% | 13.3% |
| Zydus Lifesciences ZYDUSLIFE | ₹1.1 L Cr | 24.6× | 4.1× | 20.3× | 16.7% | 16.7% | 16.3% |
| Cipla CIPLA | ₹1.1 L Cr | 29.1× | 3.3× | — | 11.3% | 13.8% | 7.4% |
| Dr Reddy's Laboratories DRREDDY | ₹1.1 L Cr | 25.2× | 2.8× | — | 11.1% | 12.5% | 11.0% |
| Mankind Pharma MANKIND | ₹98,725 Cr | 51.7× | 6.0× | 29.1× | 11.7% | 13.4% | 17.7% |
| Biocon BIOCON | ₹67,470 Cr | 145.1× | 1.9× | 25.6× | 1.1% | 2.3% | 14.8% |
| Alkem Laboratories ALKEM | ₹63,998 Cr | 27.8× | 4.6× | 22.8× | 16.7% | 15.6% | 8.2% |
| Abbott India ABBOTINDIA | ₹55,558 Cr | 35.7× | 11.6× | 29.4× | 32.5% | 22.4% | 9.0% |
Aurobindo trades at a discount to sector peers on P/E (24.9× vs median 32.4×). This may signal undervaluation — or reflect lower expected growth or higher perceived risk versus the peer group.
Business quality
Key profitability, efficiency, and solvency metrics.
Financial health
Piotroski F-Score, Altman Z-Score, and key solvency ratios.
Full financial data
Charts and annual statements for income, balance sheet and cash flow.
Income trend
Revenue, profit and margin trends over time.
Cash flow
Where cash comes from and where it goes.
Balance sheet
Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.